Advertisement

A Forecast for Application of Cyclodextrins in the Pharma-Industry

  • Á. Stadler-Szőke
  • J. Szejtli
Part of the Advances in Inclusion Science book series (AIS, volume 1)

Summary

During the last decade a rapidly increasing activity was reflected in the number of papers and patents dedicated to the pharmaceutical application of CD-s.

The main results of these investigations should be summarised as follows:
  1. a./

    on account of solubility and toxicity reasons the β -CD — until now the only industrially produced CD — can be utilized in oral and rectal preparations

     
  2. b./

    the main features of complexation of active ingradients by β -CD are the stabilization of labile compounds and enhancement of bioavsilability

     
  3. c./

    the accumulated knowledge on this field allow to set limits with acceptable certainty to the group of drugs, which can be and which are worth of transformation into CD-complex.

     

Shape, size and hydrophobicity of molecules are the main factors in determining the complexability.

About 10 % of orally applied drugs — their active ingredient — seems to be complexable; about half of these cases one or other physical or chemical properties can be modified up to such an extent, which give reason of CD complexation.

Taking into account all factors, in at least 2 % of all actually produced tablets the presence of CD as complexing agent /or auxiliary substance/ is favourable. It means, that in a not too far future a several thousand ton fraction of the β -CD market might be consumed by the pharmaceutical industry for production of oral preparations.

Keywords

Inclusion Complex Guest Molecule Anthranilic Acid Cyclodextrin Complexation Japan Patent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature Cited

  1. 1.
    Szejtli, J.: Cyclodextrins and their Inclusion Complexes, Akadémiai Kiadó, Budapest, 1981.Google Scholar
  2. 2.
    Szejtli, J.: Die Stärke, 33 in press (1981)Google Scholar
  3. 3.
    Bender, M.L. and Komiyama, M.: Cyclodextrin Chemistry, Springer Verlag, Berlin-Heidelberg-New York, 1978.CrossRefGoogle Scholar
  4. 4.
    Uekama, K., Hirayama, F. and Irie, T.: Chem.Lett. (Japan) 661 (1978)Google Scholar
  5. 5.
    Uekama, K., Hirayama, F., Ikeda, K. and Inaba, K.: J.Pharm. Sci., 66 706 (1977)CrossRefGoogle Scholar
  6. 6.
    Uekama, K., Hirayama, F., Wakuda, T. and Otagiri, M.: Chem.Pharm. Bull. 29 213 (1981)CrossRefGoogle Scholar
  7. 7.
    Uekama, K., Hirayama, F., Otagiri, M., Ikeda, K.: Chem.Pharm. Bull. 26 1162 (1978)CrossRefGoogle Scholar
  8. 8.
    Ikeda, K., Uekama, K., Otagiri, M., Hatano, M.: J.Pharm.Sci. 63 1168 (1974)CrossRefGoogle Scholar
  9. 9.
    Van Etten, R.L., Sebastian, J.F., Clowes, G.A. and Bender, M.L.: J.Amer.Chem.Soc., 89 3242 (1967)CrossRefGoogle Scholar
  10. 10.
    Griffiths, D.W. and Bender, M.L.: Adv. Cat., 23 209 (1973)CrossRefGoogle Scholar
  11. 11.
    Uekama, K., Matsuo, N., Hirayama, F., Yamaguchi, T., Imamura, Y., Ichibagase, H.: Chem.Pharm.Bull. 27 398 (1979)CrossRefGoogle Scholar
  12. 12.
    Frömming, K.H., Weyermann, I.: Arzneim. Forschung 23 424 (1973)Google Scholar
  13. 13.
    Pujimoto, S.: Japan Kokai, 78,124,607 /1978/Google Scholar
  14. 14.
    Nakai, Y.: Japan Kokai, 79 86 607 (1979)Google Scholar
  15. 15.
    Kurozumi, M., Nambu, N., Nagai, T.: Chem. Pharm.Bull. 23 3062 (1975)CrossRefGoogle Scholar
  16. 16.
    Nagai, T., Nambu, N., Shimoda, M., Takahashi, Y.: Expo.Congr. Int. Technol. Pharm., 1st 4 204 (1977)Google Scholar
  17. 17.
    Nambu, N., Shimoda, M., Takahashi, Y., Ueda, H., Nagai, T.: Chem.Pharm.Bull. 26 2952 (1978)CrossRefGoogle Scholar
  18. 18.
    Szejtli, J., Szente, L.: Pharmazie 36 694 (1981)Google Scholar
  19. 19.
    Nambu, N., Shimoda, M., Takahashi, Y., Ueda, H., Nagai, T.; Chem.Pharm.Bull. 26 2952 (1978)CrossRefGoogle Scholar
  20. 20.
    Sankyo KK: Japan Patent 119818 (1976)Google Scholar
  21. 21.
    Ohta Pharm. Co., Ltd.: Japan Kokai 81 34 618 (1981)Google Scholar
  22. 22.
    Kurosumi, M., Nambu, N., Nagai, T.: Chem.Pharm.Bull. 23 3062 (1975)CrossRefGoogle Scholar
  23. 23.
    Koizumi, K., Hiroko, M., Kubota, Y.: Chem.Pharm.Bull. 28 319 (1980)CrossRefGoogle Scholar
  24. 24.
    Szejtli, J., Bolla-Puaztai, É., Szabó, P. and Ferenczy, T.: Pharmazie, 35 779 (1980)Google Scholar
  25. 25.
    Hayashi, M., Ishihara, T.: Japan Patent 50 119 70 (1971)Google Scholar
  26. 26.
    Hayashi, H., Nishibori, T.: Japan Patent 4 739 057 (1972)Google Scholar
  27. 27.
    Hatachie, Y., Inaba, K.: Japan Kokai 74 26 416 (1974)Google Scholar
  28. 28.
    Kawasaki, A., Nakai, K., Ishii, A., Akimoto et al.: Oyo Yakuri 8 61 (1974)Google Scholar
  29. 29.
    Nislibori, T., Matsuoka, Y., Matsumoto, T.: Oyo Yakuri 8 795 (1974)Google Scholar
  30. 30.
    Szejtli, J., Szejtli, M., Cseh, Gy., Stadler, I.: Hung.Patent Appl. CI-1770 (1977)Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1982

Authors and Affiliations

  • Á. Stadler-Szőke
    • 1
  • J. Szejtli
    • 1
  1. 1.CHINOIN Pharmaceutical-Chemical WorksBudapestHungary

Personalised recommendations